Kyverna Therapeutics, Inc. Common Stock (KYTX) — Financial Flexibility Index
Kyverna Therapeutics, Inc. Common Stock (KYTX) has a Financial Flexibility Index of -0.68x as of March 2026. Free cash flow of $-41.60 Million (operating CF $-41.60 Million minus capex $0.00) represents -1% of total liabilities ($61.44 Million). Check Kyverna Therapeutics, Inc. Common Stock tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Kyverna Therapeutics, Inc. Common Stock Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for Kyverna Therapeutics, Inc. Common Stock across 5 annual periods. For the full cash flow conversion analysis, see Kyverna Therapeutics, Inc. Common Stock (KYTX) cash flow conversion.
Annual Financial Flexibility Index for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
Year-by-year free cash flow to debt coverage for Kyverna Therapeutics, Inc. Common Stock. Explore Kyverna Therapeutics, Inc. Common Stock (KYTX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.50x | $-153.71 Million | $-153.71 Million | $61.55 Million | ▲ +15.2% |
| 2024 | -2.94x | $-112.05 Million | $-114.25 Million | $38.06 Million | ▼ -47.9% |
| 2023 | -1.99x | $-51.79 Million | $-52.41 Million | $26.02 Million | ▼ -14.0% |
| 2022 | -1.75x | $-35.34 Million | $-36.11 Million | $20.25 Million | ▼ -1002.2% |
| 2021 | -0.16x | $-20.87 Million | $-22.16 Million | $131.74 Million | — |